PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy

Lung Cancer

Volumn 71, Issue 1, 2011, Pages 82-88

  Pu, Xia ^a   Hildebrandt, Michelle A T ^a   Lu, Charles ^a   Lin, Jie ^a   Stewart, David J ^a   Ye, Yuanqing ^a   Gu, Jian ^a   Spitz, Margaret R ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AKT; Chemotherapy; Clinical outcomes; Lung cancer; Platinum agents

Indexed keywords

CARBOPLATIN; CISPLATIN DERIVATIVE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ADULT; AGED; ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TOR SERINE-THREONINE KINASES;

EID: 78651359460     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.04.008     Document Type: Article

References (32)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Ries L.A.G., Melbert D., Krapcho M., Stinchcomb D.G., Howlader N., Horner M.J., et al. SEER Cancer Statistics Review, 1975-2005 2008, National Cancer Institute, Bethesda, MD.
3. Spira A., Ettinger D.S. Multidisciplinary management of lung cancer. N Engl J Med 2004, 350:379-392.
4. Burdett S., Stephens R., Stewart L., Tierney J., Auperin A., Le Chevalier T., et al. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625.
5. Kartalou M., Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat Res 2001, 478:23-43.
6. Rabik C.A., Dolan M.E. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007, 33:9-23.
7. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
8. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
9. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14:381-395.
10. Gagnon V., Van Themsche C., Turner S., Leblanc V., Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 2008, 13:259-271.
11. Kim S.H., Juhnn Y.S., Song Y.S. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Ann N Y Acad Sci 2007, 1095:82-89.
12. Lee S., Choi E.J., Jin C., Kim D.H. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Gynecol Oncol 2005, 97:26-34.
13. Liu L.Z., Zhou X.D., Qian G., Shi X., Fang J., Jiang B.H. AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 2007, 67:6325-6332.
14. Yang X., Fraser M., Moll U.M., Basak A., Tsang B.K. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006, 66:3126-3136.
15. Hildebrandt M.A., Yang H., Hung M.C., Izzo J.G., Huang M., Lin J., et al. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 2009, 27:857-871.
16. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655.
17. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
18. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995, 57:289-300.
19. Pisick E., Jagadeesh S., Salgia R. Receptor tyrosine kinases and inhibitors in lung cancer. Sci World J 2004, 4:589-604.
20. Bader A.G., Kang S., Zhao L., Vogt P.K. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005, 5:921-929.
21. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005, 4:988-1004.
22. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
23. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
24. Lee M.W., Kim D.S., Min N.Y., Kim H.T. Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin. Int J Cancer 2008, 122:2380-2384.
25. Sanborn R.E. Cisplatin versus carboplatin in NSCLC: is there one "best" answer?. Curr Treat Options Oncol 2008, 9:326-342.
26. Forgacs E., Biesterveld E.J., Sekido Y., Fong K., Muneer S., Wistuba I.I., et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 1998, 17:1557-1565.
27. Marsit C.J., Zheng S., Aldape K., Hinds P.W., Nelson H.H., Wiencke J.K., et al. PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol 2005, 36:768-776.
28. Petersen S., Rudolf J., Bockmuhl U., Gellert K., Wolf G., Dietel M., et al. Distinct regions of allelic imbalance on chromosome 10q22-q26 in squamous cell carcinomas of the lung. Oncogene 1998, 17:449-454.
29. Soria J.C., Lee H.Y., Lee J.I., Wang L., Issa J.P., Kemp B.L., et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002, 8:1178-1184.
30. Yokomizo A., Tindall D.J., Drabkin H., Gemmill R., Franklin W., Yang P., et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 1998, 17:475-479.
31. Shayesteh L., Lu Y., Kuo W.L., Baldocchi R., Godfrey T., Collins C., et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999, 21:99-102.
32. Brognard J., Clark A.S., Ni Y., Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001, 61:3986-3997.